Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,956 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormones Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jul 21, 2026, 1:13 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

NCT05059236
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women

NCT01340521
View directory record Official record
Conditions
Infertility
Interventions
Clomiphene Citrate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 1994
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Estrogen Treatment on Drug Metabolism and Transport

NCT05469204
View directory record Official record
Conditions
Transgender Persons
Interventions
Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet, Midazolam Injectable Solution
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

NCT01560416
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Ganetespib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 21, 2026, 1:13 PM EDT
Completed No phase listed Observational

Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy

NCT00179426
View directory record Official record
Conditions
Seizure Disorder, Epilepsy
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 21, 2026, 1:13 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand

NCT04876378
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Jul 21, 2026, 1:13 PM EDT
Recruiting Phase 2 Interventional

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

NCT07227233
View directory record Official record
Conditions
Breast Cancer
Interventions
A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

NCT03112226
View directory record Official record
Conditions
Cognitive Impairment, Estrogen Deficiency, Menopause, Endothelial Dysfunction, Vascular Stiffness
Interventions
GnRHant + E2, GnRHant + Placebo
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 2 Interventional

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

NCT00257478
View directory record Official record
Conditions
Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
Interventions
YM155
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
7
States / cities
Tuscon, Arizona • Los Angeles, California • Coeur d'Alene, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Smoking, Sex Hormones, and Pregnancy

NCT01811225
View directory record Official record
Conditions
Nicotine Dependence, Contraception
Interventions
Low-dose Progesterone, High-dose Progesterone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Jul 21, 2026, 1:13 PM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 1:13 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

NCT07137871
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Avasopasem
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 2 Interventional

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

NCT00039104
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, zoledronic acid, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 2 Interventional

Serologically Active, Clinically Stable Systemic Lupus Erythematosus

NCT00000421
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Prednisone, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
13 Years to 65 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
3
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

NCT00675506
View directory record Official record
Conditions
Abdominal Obesity, Growth Hormone Deficiency
Interventions
Growth hormone releasing hormone (GHRH) 1-44, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Jul 21, 2026, 1:13 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

NCT04616963
View directory record Official record
Conditions
Hiv, Hormone Therapy
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir Alafenamide 200/25 mg
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 21, 2026, 1:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers

NCT00001953
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 1:13 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 1Phase 2 Interventional

Versartis Trial in Children to Assess Long-Acting Growth Hormone

NCT01718041
View directory record Official record
Conditions
Pediatric Growth Hormone Deficiency
Interventions
Experimental: VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Clovis, California • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Phase 1 Interventional Results available

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

NCT03099174
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms
Interventions
Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Not applicable Interventional Results available

Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial

NCT03783546
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Usual Care
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Pilot Study on Energy Therapy or Massage to Reduce Fatigue

NCT02758756
View directory record Official record
Conditions
Fatigue
Interventions
Massage, Reiki
Other
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 21, 2026, 1:13 PM EDT